For the year ending 2025-12-31, CELU made $26,550K in revenue. -$91,800K in net income. Net profit margin of -345.76%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenues | 26,550 | |||
| Change in fair value of contingent consideration liability | 0 | |||
| Research and development | 15,025 | |||
| Selling, general and administrative | 51,266 | |||
| Amortization of acquired intangible assets | 1,493 | |||
| Cost of revenues | 20,074 | |||
| Total operating expenses | 87,858 | |||
| Loss from operations | -61,308 | |||
| Interest income | 262 | |||
| Interest expense | 6,754 | |||
| Change in fair value of warrant liabilities | 3,318 | |||
| Change in fair value of derivative liability | 65 | |||
| Change in fair value of debt | 1,809 | |||
| Loss on debt extinguishment | -6,356 | |||
| Amortization of licensing obligation premium | 1,911 | |||
| Loss on issuance of convertible notes with warrants | -2,335 | |||
| Impairment of preferred stock investment | 2,890 | |||
| Compliance fees and other expense, net | -9,181 | |||
| Total other expense | -30,405 | |||
| Loss before income taxes | -91,713 | |||
| Income tax expense (benefit) | 3 | |||
| Net loss | -91,716 | |||
| Deemed dividend relating to inducement of dragasac warrants | 64 | |||
| Paid-in kind preferred stock dividend | 20 | |||
| Net loss attributable to common shareholders | -91,800 | |||
| Basic EPS | -3.59 | |||
| Diluted EPS | -3.59 | |||
| Basic Average Shares | 25,598,586 | |||
| Diluted Average Shares | 25,598,586 | |||
Celularity Inc (CELU)
Celularity Inc (CELU)